TY - JOUR
T1 - Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension
AU - Nootens, M.
AU - Schrader, B.
AU - Kaufmann, E.
AU - Vestal, R.
AU - Long, W.
AU - Rich, S.
N1 - Funding Information:
Supported in part by the Department of Veterans Affairs (Office of Research ana Development, Medical Research Service) and by Burrough Wellcome Co.
PY - 1995
Y1 - 1995
N2 - Vasodilators have been a main focus of therapy for primary pulmonary hypertension. Adenosine and prostacyclin have been shown to reduce pulmonary vascular resistance acutely in these patients. In order to compare the acute hemodynamic effects of adenosine and prostacyclin, ten patients with severe primary pulmonary hypertension, unresponsive to medical therapy, were studied. After baseline hemodynamics were obtained, an adenosine infusion, 50 to 100 ng/kg/min, was begun and titrated to the maximum tolerated dose. Hemodynamics were allowed to return to baseline, and thereafter, a prostacyclin infusion was begun at 2 ng/kg/min, and titrated to the maximum tolerated dose. Overall, adenosine (200 ± 53 ng/kg/min) produced a 33 ± 18% (p<0.001) fall in pulmonary vascular resistance and a 52 ± 25% (p<0.001) increase in cardiac output with no effect on pulmonary or systemic arterial pressures. Prostacyclin (8 ± 4 ng/kg/min) caused a 22 ± 18% (p<0.01) fall in pulmonary vascular resistance and a 25 ± 26% (p<0.05) increase in cardiac output with a 14 ± 6% (p<0.001) decrease in systemic arterial pressure, but no change in pulmonary arterial pressure. The effects of adenosine and prostacyclin on pulmonary vascular resistance were similar (r=0.70, r2=0.49, p=0.02). Adenosine and prostacyclin have similar hemodynamic effects acutely in primary pulmonary hypertension. Adenosine may be useful as a test of the potential for long-term prostacyclin therapy in patients with primary pulmonary hypertension.
AB - Vasodilators have been a main focus of therapy for primary pulmonary hypertension. Adenosine and prostacyclin have been shown to reduce pulmonary vascular resistance acutely in these patients. In order to compare the acute hemodynamic effects of adenosine and prostacyclin, ten patients with severe primary pulmonary hypertension, unresponsive to medical therapy, were studied. After baseline hemodynamics were obtained, an adenosine infusion, 50 to 100 ng/kg/min, was begun and titrated to the maximum tolerated dose. Hemodynamics were allowed to return to baseline, and thereafter, a prostacyclin infusion was begun at 2 ng/kg/min, and titrated to the maximum tolerated dose. Overall, adenosine (200 ± 53 ng/kg/min) produced a 33 ± 18% (p<0.001) fall in pulmonary vascular resistance and a 52 ± 25% (p<0.001) increase in cardiac output with no effect on pulmonary or systemic arterial pressures. Prostacyclin (8 ± 4 ng/kg/min) caused a 22 ± 18% (p<0.01) fall in pulmonary vascular resistance and a 25 ± 26% (p<0.05) increase in cardiac output with a 14 ± 6% (p<0.001) decrease in systemic arterial pressure, but no change in pulmonary arterial pressure. The effects of adenosine and prostacyclin on pulmonary vascular resistance were similar (r=0.70, r2=0.49, p=0.02). Adenosine and prostacyclin have similar hemodynamic effects acutely in primary pulmonary hypertension. Adenosine may be useful as a test of the potential for long-term prostacyclin therapy in patients with primary pulmonary hypertension.
KW - adenosine
KW - primary pulmonary hypertension
KW - prostacyclin
UR - http://www.scopus.com/inward/record.url?scp=0028873863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028873863&partnerID=8YFLogxK
U2 - 10.1378/chest.107.1.54
DO - 10.1378/chest.107.1.54
M3 - Article
C2 - 7813311
AN - SCOPUS:0028873863
SN - 0012-3692
VL - 107
SP - 54
EP - 57
JO - Diseases of the chest
JF - Diseases of the chest
IS - 1
ER -